Business Wire

One IBC Group Focuses on Digital Transformation and Innovation in the Corporate Service Industry

23.3.2022 12:00:00 EET | Business Wire | Press release

Share

One IBC Group, an international corporate service provider with 12 years of experience and a global outreach, highlighted in its 2022 action plan that technology is going to be the company’s main focus of growth. Through digital transformation and innovation, One IBC Group believes not only its services and operations will drastically improve, but the whole industry will also benefit and change the way it traditionally works.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220323005053/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

One IBC’s services can be accessed on different platforms (Photo: Business Wire)

The quest for digital transformation

In recent years, a majority of businesses have shifted their focus on technology and innovation in order to improve operational efficiency and further connect their services to their customers. With the help of revolutionary technologies such as CRMs, mobile apps, websites, etc., businesses have now been able to simplify their operations, tailor their products and services, and adapt to the various needs of their clients.

With that being said, not every industry can embark on the digitalized trend as quickly. Corporate service is a good example. Most, if not all, corporate service providers on the market right now are still using the same technology of 20 years ago. Though the services can be processed entirely remotely, and some can even be done automatically, no significant change has been made since then, while customer demand is increasing from time to time.

For an industry that has so much potential for digital transformation, corporate service is looking for a game-changing breakthrough.

One IBC Group’s plan to innovate

Since it was founded, One IBC Group has been using technology to remotely provide corporate services around the world. To be able to grow faster and compete with big players in the industry, the company decided to focus more on technology development.

In its 2022 action plan, One IBC Group emphasizes that digital transformation and innovation will be its primary mission. The plan set out a 5-year roadmap pinpointing each goal that needed to be achieved in a set time to upgrade the system and apply new technology. It includes automating the service order process, optimizing the operation procedures, building a client portal, incorporating software-as-a-service (SaaS) platforms, and constantly updating the whole system.

“It is no longer the future. The race for innovation is the new norm now,” said Jimmy Lee, CEO of One IBC Group. “With a solid technology foundation that we are having now, we believe One IBC Group can make a revolution in the corporate service industry.”

Prior to that, in 2021, One IBC Group had introduced its first mobile app. It was created with the goal of enhancing and improving client experience as well as introducing a new way to set up overseas businesses.

“This is just the beginning,” Jimmy said. “We are trying to provide more services and integrate them into our platforms as part of our ongoing development and extension, at the same time create a whole ecosystem for businesses to build their global expansion strategies.”

About One IBC Group

One IBC Group is a leading corporate service provider with global experience and delivery capabilities.

Since its beginning, One IBC Group has strived to provide global expansion strategies to entrepreneurs, investors, and business owners worldwide, with services ranging from company formation, trademark and license registration, to office and secretarial services. It has been building connections with international partners and using advanced technology to provide the best services to its clients.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Tyler Wong
Operation Director
tyler.wong@oneibc.com
(949) 864-6011
https://www.oneibc.com/

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye